IT TEST

May 11, 2009 04:22 ET | Source: Santhera Pharmaceuticals Holding AG Santhera Pharmaceuticals Holding AG

TEST - Please disregard this message

Recommended Reading

January 15, 2026 01:00 ET | Source: Santhera Pharmaceuticals Holding AG

Santhera Receives Swissmedic Approval of AGAMREE® (Vamorolone) for the Treatment of Duchenne Muscular Dystrophy

Commercial launch in Switzerland anticipated in H2 2026 Pratteln, Switzerland, January 15, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces that the Swiss Agency for Therapeutic Products...
Read More
January 08, 2026 02:16 ET | Source: Santhera Pharmaceuticals Holding AG

Santhera Licenses AGAMREE® (Vamorolone) to Nxera Pharma in Japan, South Korea, Australia and New Zealand in a Deal Valued at up to USD 205 Million Plus Royalties

Ad hoc announcement pursuant to Art. 53 LR Exclusive licensing agreement includes USD 40 million upfront comprising USD 30 million in cash and USD 10 million equity investment at CHF 14.91 per share,...
Read More